Brief: Shanghai Henlius Biotech Says FDA Approves IND Application For Hlx15-SC For Multiple Myeloma
16/02/2026 06:42
Feb 16 (Reuters) - Shanghai Henlius Biotech 2696.HK: FDA APPROVES IND APPLICATION FOR HLX15-SC FOR MULTIPLE MYELOMA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln